(Treatment Failure Trial)

Slides:

Advertisements

Similar presentations

Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir (BOC) Plus PEGINTRON (PegInterferon Alfa-2b) and.

Advertisements

HCV RESPOND-2 Final Results High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re-

Hepatitis C The next generation of Treatment for Hepatitis C.

Hepatitis web study Hepatitis web study Sofosbuvir in Genotype 2 or 3 FUSION Trial Phase 3 *Note: Published in NEJM in tandem with POSITRON Trial (GT 2,3.

Future Directions in HCV Therapy Eric Lawitz, MD, AGAF,CPI Medical Director, The Texas Liver Institute Clinical Professor of Medicine University of Texas.

What’s new in HCV genotype 2? Alessandra Mangia S.Giovanni Rotondo,ITALY PARIS HEPATITIS CONFERENCE January 2012.

Management of Chronic Hepatitis C in 2013

Protease and Polymerase Inhibitors for the Treatment of Hepatitis C

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.

Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto Protease Inhibitors in Chronic Hepatitis C: An Update.

How to manage non responders Lawrence Serfaty Service d’Hépatologie, UMR S 893 Hôpital Saint-Antoine, UPMC, Paris Clinical case 1.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3 PROTON Phase 2 Treatment Naïve Lawitz E, et al. Lancet.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.

Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-2 Trial Phase 3 Treatment Naïve Manns M, et al. Lancet.

Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Jacobson IM, et al.

Hepatitis web study Hepatitis web study PEG alfa-2a + RBV versus PEG alfa-2a versus INF + RBV APRICOT STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.

Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin for 12 or 24 Weeks in GT 2,3 Phase 3 Treatment Naïve, Chronic HCV Mangia A, et.

Hepatitis C Genotype 3 Paris 2012 Graham R Foster Professor of Hepatology Queen Marys School of Medicine Barts and The London.

ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:

Controversies: Lead in or no lead in ? PRO Controversies: Lead in or no lead in ? PRO Lawrence Serfaty Hôpital Saint-Antoine Paris 5th Paris Hepatitis.

Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.

Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.

Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Boceprevir (Victrelis) Prepared by: David Spach, MD & H. Nina Kim, MD Last Updated: March.

SPRINT-2/RESPOND-2 Boceprevir Plus Standard of Care Phase 3 Clinical Trials Analysis of Resistance Associated Variants by HCV Genotype 1 subtypes 1a and.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Management of Patients Co- infected with HCV and HIV: A Close Look at the Role for DAAs Susanna Naggie, MD Assistant Professor of Medicine Division of.

ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:

Update on the HCV Antiviral Pipeline Todd S. Wills, MD SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center Infectious Disease.

Triple Therapy Today: Phase III Results in G1 Relapsers and Nonresponders Bruce R. Bacon, M.D. James F. King MD Endowed Chair in Gastroenterology Professor.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

Response Guided Therapy Fabien Zoulim Hepatology Department & INSERM Unit 1052, Lyon University Lyon, France.

Hepatitis web study Hepatitis web study Simeprevir with Peginterferon and Ribavirin in GT-4 RESTORE Phase 3 Treatment Naïve and Treatment Experienced Moreno.

How to optimize treatment of G1 patients? Prof. G. K. K. Lau 2012.

How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal.

Hepatitis C Nonresponders

AASLD 2010 HCV Feedback October 29 - November 2, 2010 Boston, Massachusetts Dr Allister J Grant Consultant Hepatologist Leicester Liver Unit.

Hepatitis web study Hepatitis web study Boceprevir with PEG + RBV in Genotype 1 SPRINT-1 Phase 2 Treatment Naïve Kwo PY, et al. Lancet. 2010;376:

Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.

 Design Open-label years Chronic HCV infection Genotype 1 HCV RNA > 10,000 IU/mL HIV co-infection Stable ART* with HIV RNA < 50 c/mL ≥ 24 weeks.

EASL 2013 Ivan Gardini. MY PERSONAL VIETNAM 20 YEARS OF CHRONIC HEPATITS 5 TREATMENTS FAIELD 3 CIRRHOSIS 2 LIVER TRANSPLANT.

Maria Buti,1 Yoav Lurie,2 Natalia G. Zakharova,3 Natalia P. Blokhina,4 Andrzej Horban,5 Gerlinde Teuber,6 Christoph Sarrazin,6 Ligita Balciuniene,7 Saya.

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

Phase 2b Treatment-Naïve

Phase 2 Treatment Naïve HIV Coinfection

DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

HCV SPRINT-1 Final Results SVR 24 Boceprevir

Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals Susanna Naggie, Mark S. Sulkowski Gastroenterology

Boceprevir in Treatment Naive SPRINT-2

Simeprevir in HIV Coinfection, GT-1 C212 Trial

HCV Protease Inhibitors in Clinical Practice

Analysis of Sustained Viral Response and Boceprevir Resistance Following Combination Treatment With Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in.

Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study

SPRINT-2 Design (Naïve Study)

PI-Based HCV-1 Therapy: Reasons to Hold Off

ASPIRE Study: SMV + PEG-IFN + RBV for genotype 1 experienced patients

HCV Protease Inhibitors in Clinical Practice

New HCV therapies on the horizon

Why We Should Be Willing to Pay for Hepatitis C Treatment

What do data in monoinfection mean in relation to co-infection?

What Does the Future Hold and What Will It Mean for Patients?

Covering the Cover Gastroenterology

Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)

CONCERTO-4 Study: SMV + PEG-IFNa-2b + RBV for genotype 1

Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Presentation transcript:

(Treatment Failure Trial) RESPOND-2 Study Design (Treatment Failure Trial) Weeks 12 24 48 72 Arm 1 : SOC Comparator CONTROL PEG + RBV 4 wk Placebo + PEG + RBV 44 wk Follow-up 24 wk TW 8 HCV-RNA Undetectable SCREENING Arm 2 : Response Guided Therapy Follow-up 36 wk PEG + RBV 4 wk BOC + PEG + RBV 32 wk TW 8 HCV-RNA Detectable/TW 12 Undetectable Placebo + PEG + RBV 12 wk Follow-up 24 wk EXPERIMENTAL ARMS Arm 3: SOC + Boceprevir PEG + RBV 4 wk BOC+ PEG + RBV 44 wk Follow-up 24 wk